Efficacy of Fluvastatin and Fenofibrate in Comparison to Simvastatin and Ezetimibe in Patients With Metabolic Syndrome
This study will investigate the effects of the combination of fluvastatin and fenofibrate on dyslipidemia in comparison to the combination of simvastatin and ezetimibe...
Brief Summary
Official Title: “A 16-week Multicenter, 2-period Study to Investigate the Effect of the Combination of Fluvastatin ER 80mg and Fenofibrate 200mg on HDL-C in Comparison to the Combination of Simvastatin 20mg and Ezetimibe 10mg in Patients With Metabolic Syndrome”
This study will investigate the effects of the combination of fluvastatin and fenofibrate on dyslipidemia in comparison to the combination of simvastatin and ezetimibe.
- Study Type: Interventional
- Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
- Study Primary Completion Date: March 2007
Intervention(s) in this Clinical Trial
- Drug: Fluvastatin extended release, fenofibrate
- Drug: Fixed combination simvastatin/ezetimibe
Outcome Measures for this Clinical Trial
Primary Measures
- High density lipoprotein cholesterol (HDL-C) measured at the end of each study period.
Secondary Measures
- Compared at the end of each treatment period:
- patients reaching target levels of low density lipoprotein cholesterol (LDL-C) <100mg/dl
- patients reaching target levels of non-HDL-C <130mg/
- LDL-C/HDL-C
- Triglycerides
- LDL subfractions in a subgroup of patients
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Written informed consent to participate in the study prior to any study procedures.
- Male or female subjects, age between 18-75 years inclusive.
- All women of child bearing potential must have a negative pregnancy test
- Metabolic Syndrome according to the International Diabetes Federation definition:
- Low plasma HDL-C (Men < 40 mg/dl ; Women < 50 mg/dl ).
- Elevated waist circumference (men ≥ 94 cm, women ≥ 80cm)
- And one or more of the following criteria:
- Triglycerides ≥ 150 mg/d.l
- Raised blood pressure (DBP ≥ 85 mmHg and/or SBP ≥ 130mmHg ) or treated hypertension.
- Fasting plasma glucose≥ 100mg/dl.
- Previously diagnosed type 2 diabetes.
Exclusion Criteria:
- Dyslipidemia secondary to other causes such as nephrotic syndrome, autoimmune disease.
- Type 1 diabetes.
- HbA1c > 9.5%.
- Unexplained serum creatine phosphokinase > 2 x Upper limit of normal.
- History of myocardial infarction and/or cerebral stroke and/or unstable angina pectoris.
- Known or suspected contraindications and warnings according to the country specific label for the investigational drugs.
- Other protocol-defined inclusion/exclusion criteria may apply.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 75 Years
Clinical Trial Investigator Information
Lead Investigator: Novartis Industry
Overall Clinical Trial Officials and Contacts
Novartis Pharma AG Study Director Novartis
Additional Information
Information obtained from ClinicalTrials.gov on February 09, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00385658
Study ID Number: CXUO320BDE35
ClinicalTrials.gov Identifier: NCT00385658
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00385658
